---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-006962"
form_type: "8-K"
ticker: "ODYY"
cik: "0001626644"
company_name: "Odyssey Health, Inc."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:00:49.403219+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Odyssey Health sells neurological drug pipeline to Oragenics for $1M and 8M preferred shares

## Summary
- Oragenics to acquire Odyssey's assets including concussion drug ONP-002 and NPC candidate; cash payment of $1M and 8M Series F Preferred Shares.
- Transaction expected to close Q4 2023, subject to shareholder approvals and other conditions, including Oragenics having ≥$5M cash at close.
- ONP-002 completed Phase 1 trial; Phase 2 preparation underway; animal studies show reduced swelling, inflammation, oxidative stress.
- Odyssey management members intend to join Oragenics post-close to continue development.
- Odyssey retains other assets and operations; Oragenics expands into neurological therapeutics via intranasal delivery.

## SEC filing metadata
- accession: 0001683168-23-006962
- form_type: 8-K
- ticker: ODYY
- cik: 0001626644
- company_name: Odyssey Health, Inc.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/0001683168-23-006962-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/odyssey_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-006962
- JSON: https://secwatch.observer/filing/0001683168-23-006962.json
- Plain text: https://secwatch.observer/filing/0001683168-23-006962.txt

## Key facts
- Material Agreements
  Odyssey Health, Inc. entered into Asset Purchase Agreement with Oragenics, Inc. valued at $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (effective 2023-10-04).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Oragenics, Inc.
  - Value: $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock
  - Effective: 2023-10-04
  source text: On October 4, 2023, Odyssey Health, Inc. (f/k/a Odyssey Group International, Inc., a Nevada corporation (“ Odyssey ” the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Oragenics, Inc. (“ Oragenics ” the “ Purchaser ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626644/000168316823006962/0001683168-23-006962-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.